Another victory: Huge hedge funds begin selling away Monsanto stock amid too much ‘drama’ Well, it’s not been a good year, stock-sensible, for Monsanto, and we’re alright with that impotence . The mega-biotech organization has seen its shares roller-coaster for weeks, struggling to get a decent run amid constant chaos in the marketplace, not the least which has been the selling of Monsanto share by big hedge money. That marketplace chaos offers stemmed, in huge part, from expanding knowing of genetically altered seeds and foods, the creation which Monsanto has performed the biggest role.
Annexin-Vivo 750 imaging agent for measuring cell death in vivo VisEn Medical Inc., a head in fluorescence in vivo imaging from study through medicine, announced today the industrial launch of its new Annexin-Vivo 750 imaging agent for measuring and monitoring apoptosis and cell loss of life in vivo. The new Annexin-Vivo 750 agent is founded on the more developed Annexin labeling standard in in vitro study. It is likely to significantly expand research areas and enhance medication development by enabling real-time imaging of apoptosis and cell loss of life biomarkers associated with disease progression and therapeutic response in vivo. Annexin-Vivo 750 targets membrane-bound phosphatidylserine uncovered in the outer leaflet of the plasma membrane during the induction of apoptosis and cell loss of life.